FLOHALE 0.5MG RESP

Targeted Bronchopulmonary Delivery with Minimal Systemic Impact:
Flohale 0.5mg Respules harnesses the power of direct nebulized delivery to concentrate anti-inflammatory action precisely at the bronchial mucosa where it is needed most. Because the active compound reaches target tissues without significant first-pass systemic absorption, your feline or canine companion benefits from powerful airway control while the systemic steroid burden remains substantially lower than with oral prednisolone therapy.

Suppresses the Immunological Root of Airway Inflammation:
Rather than merely relaxing bronchial smooth muscle temporarily, Flohale 0.5mg Respules works upstream at the cellular and transcriptional level to curtail the release of eosinophilic and neutrophilic inflammatory mediators that perpetuate chronic airway disease. This makes it particularly well suited as a cornerstone of long-term maintenance therapy, progressively reducing airway hyperreactivity and supporting sustained remission of clinical signs.

Clinically Validated for Feline Respiratory Disease:
Fluticasone propionate delivered via nebulization is among the most extensively studied inhaled corticosteroids in veterinary respiratory medicine, with peer-reviewed research confirming its capacity to reduce bronchial hyperresponsiveness and lower airway inflammation in cats with mild to moderate bronchial disease. Veterinary internists and feline medicine specialists widely consider it a preferred choice for long-term asthma management in cats.

Reduces Airway Oedema, Mucus Hypersecretion, and Bronchial Hyperreactivity:
The multi-pathway anti-inflammatory profile of fluticasone propionate means that Flohale 0.5mg Respules simultaneously targets vascular permeability, mucus gland overactivity, and mast cell degranulation in your companion animal's airways. Over several weeks of consistent therapy, this translates to a measurable reduction in clinical signs such as wheezing, coughing, respiratory distress, and episodes of laboured breathing.

Convenient Unit-Dose Respule Format:
Each single-use 2ml respule delivers a precise, pre-measured dose of fluticasone propionate suspension, eliminating the variability associated with multi-dose preparations and reducing the risk of dose error during home administration. The compact respule format is compatible with standard jet nebulizers used in veterinary practice and home nebulization setups.

Supports Reduction in Systemic Corticosteroid Dependence:
For animals that have been managed long-term on oral prednisolone or other systemic steroids, transitioning to or combining therapy with Flohale 0.5mg Respules under veterinary guidance can support a gradual reduction in systemic steroid exposure. This approach aligns with current best-practice recommendations in veterinary respiratory medicine, protecting your companion from the long-term consequences of systemic corticosteroid use such as diabetes mellitus, muscle wasting, and immunosuppression.

How to Use:

Flohale 0.5mg Respules 2ml must be administered exclusively by or under the direct guidance of a licensed veterinary professional. The dose, frequency, and duration of therapy will be individually determined by your veterinarian based on your companion animal's clinical diagnosis, body weight, severity of disease, and response to treatment.

Storage Advice:

Store unopened Flohale 0.5mg Respules in a cool, dry place below 25 degrees Celsius, away from direct sunlight and sources of heat. Do not freeze. Once a foil strip has been opened, individual respules should be used promptly and any unused respules from the opened strip should be stored in the original foil packaging and used within the timeframe specified by your veterinarian or the product labelling. Do not use after the best-before date printed on the foil strip or outer carton.

About the Brand:

Cipla Ltd. was founded in 1935 in Mumbai, India, by Dr. Khwaja Abdul Hamied under the founding philosophy of self-sufficiency and affordable healthcare for all. Over nine decades, Cipla has grown into a globally recognized multinational pharmaceutical leader with a presence in over 80 countries, holding USFDA approvals, WHO-GMP certifications, and operating more than 40 manufacturing facilities across India and international markets. The company has long been regarded as a global lung leader, with its respiratory portfolio spanning metered-dose inhalers, dry powder inhalers, and nebulization solutions that reflect decades of specialized R&D investment in pulmonary drug delivery systems. Cipla operates under an ESG framework anchored in environmental stewardship, social responsibility, and uncompromising product quality, guided by the enduring purpose of "Caring for Life." This commitment to innovation, accessibility, and manufacturing excellence aligns with Animeal's commitment to bringing veterinary-grade, clinically trusted products to the pets and pet parents who need them most. Discover Cipla today.

Disclaimer:

Please note that while Flohale 0.5mg Respules 2ml is formulated from fluticasone propionate, a clinically validated inhaled corticosteroid, and may be used in cats and dogs under veterinary direction for the management of chronic respiratory disease, it is a prescription-only pharmaceutical product and is not approved by regulatory authorities for veterinary use; all use in animals is off-label and must be supervised and authorized by a licensed veterinarian. This product is not a rescue bronchodilator and must not be used as a substitute for emergency veterinary intervention during acute respiratory distress or bronchospasm. For pets with a history of fungal or viral respiratory infections, tuberculosis, or known hypersensitivity to fluticasone propionate, consult your veterinarian before introducing this product. Animeal supports your pet's health and happiness journey but does not replace the advice of a qualified veterinary professional.